Onchilles Pharma Publishes Landmark ELANE Pathway Study, Advances N17350 Toward Clinical Development With New Financing and Strategic Clinical Expertise Onchilles Pharma, a privately held biotechnology company developing a new class…
CrossBridge Bio Awarded “Best Drug Developer” at the 2025 World ADC Awards, Celebrating Breakthrough Innovation in Dual-Payload ADCs CrossBridge Bio, an emerging biopharmaceutical innovator specializing in the development of next-generation…
Aulos Bioscience Unveils Encouraging New Phase 2 Data Highlighting Imneskibart’s Clinical Activity in Melanoma and Non–Small Cell Lung Cancer Aulos Bioscience, a clinical-stage immuno-oncology company advancing next-generation immune-modulating therapies, has…
AstraZeneca’s FASENRA Demonstrates Statistically Significant Clinical Benefit in Phase III NATRON Trial for Hypereosinophilic Syndrome AstraZeneca has announced positive full results from its pivotal Phase III NATRON clinical trial evaluating…
Indapta Therapeutics Showcases Promising Clinical Activity of IDP-023 Allogeneic g-NK Cell Therapy in Relapsed/Refractory Multiple Myeloma at SITC 2025 Indapta Therapeutics, Inc., a privately held, clinical-stage biotechnology company focused on…
Synthekine Unveils Encouraging Early Clinical Results for STK-012 in Combination Therapy for First-Line PD-L1–Negative Non-Squamous NSCLC at SITC 2025 Synthekine Inc., a biotechnology company advancing a new generation of engineered…
Gilead Shares Update on Phase 3 ASCENT-07 Trial Evaluating Trodelvy in HR+/HER2-Negative Metastatic Breast Cancer Gilead Sciences, Inc. (Nasdaq: GILD) has released new clinical findings from its Phase 3 ASCENT-07…
Mirum Pharmaceuticals Spotlights Advancements in Rare Liver Disease With New Data From LIVMARLI® and Volixibat Programs at AASLD’s The Liver Meeting® 2025 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biotechnology company…
Biomunex to Present Preclinical Data on MAIT Engager Platform at 2025 SITC Annual Meeting Biomunex Pharmaceuticals, an innovative French biopharmaceutical company advancing the next generation of antibody-based immunotherapies, announced that…
Northwell Study Offers Nuanced Hope for Long-Term Seizure Reduction in Chronic, Treatment-Resistant Epilepsy For millions of individuals worldwide, epilepsy remains one of the most challenging chronic neurological disorders to manage.…
ONDEX Automation Acquires PlantOPS Consulting, Expands MES and Life Sciences Capabilities ONDEX Automation has announced the acquisition of PlantOPS Consulting, a well-established specialist in Manufacturing Execution System (MES) consulting and…
Mirum Pharmaceuticals Announces Third Quarter 2025 Results and Highlights Strong Commercial Execution, Pipeline Advancement, and Strategic Positioning for 2026–2027 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company dedicated to transforming…